CD274 and neoplasm: Besides of programmed death 1 (PD-1) and its ligand PD-L1, the resent studies indicated that tumor mutational burden (TMB) could predict clinical outcomes in multiple cancer types, including lung cancer patients receiving immunotherapy (Rizvi et al., 2015, 2018; Samstein et al., 2019).